



LLCG/VZN annotations

- Both 1L nivolumab-iplimumab and 1L platinum-pemetrexed have ESMO MCBS 3. For reimbursement reasons in Belgium, a sequence starting with nivolumab-iplimumab may be preferred (PS 0-1, any histology).
- No maintenance Gemcitabine (Belgium).

LLCG/VZN annotations

- Bevacizumab not reimbursed for this indication (Belgium).
- Ramucirumab not reimbursed for this indication (Belgium).
- Vinorelbine not reimbursed for this indication (Belgium).
- No immunotherapy after 1st line reimbursed (in Belgium). Only in Clinical Trial (optional).